Search

Objective: Hypoglycemia-related neuroglycopenia disrupts cognitive-motor functioning, which can impact driving safety. Retrospective studies suggest that drivers with type 1 diabetes experience more collisions and citations than their nondiabetic spouses. We present the first prospective data documenting the occurrence of apparent neuroglycopenia-related driving performance impairments.Research Design and Methods: We completed the initial screening of 452 drivers from three geographically diverse centers who then reported monthly occurrences of driving "mishaps," including collisions, citations, losing control, automatic driving, someone else taking over driving, and moderate or severe hypoglycemia while driving.Results: Over 12 months, 52% of the drivers reported at least one hypoglycemia-related driving mishap and 5% reported six or more. These mishaps were related to mileage driven, history of severe hypoglycemia, and use of insulin pump therapy.Conclusions: Many individuals with type 1 diabetes report hypoglycemia-related driving events. Clinicians should explore the recent experiences with hypoglycemia while driving and the risk of future events. [ABSTRACT FROM AUTHOR]

The increased reliance on patient self-generated data has had a major impact on the development of the virtual team in the management of diabetes mellitus. Only recently has the concept of the virtual team been taken seriously in the management of the individual with diabetes, in part due to the availability of large amounts of patient self-generated data. Team development, especially for a virtual team, is a careful process, in which self-assessment, team building, and identification of roles and responsibilities take place before the team performs. This process has been termed `forming, storming, norming, and performing' in recognition of the stages of team development and the importance of passing through each stage before initiating the next. Research has identified four additional factors that need to be addressed for the virtual team to complete its development and to assure improved clinical outcomes: organizational support, a common approach to diabetes care based on specific clinical protocols, ongoing measurement, and incentives. The creation, organization, and implementation of virtual teams depend upon several inter-related factors. The ideal model permits synchronized communications between team members so that timely decisions can be made in a transparent manner, enabling the person with diabetes to fully participate. From a structural perspective, the team needs organizational support, common care protocols, a means of measuring performance (including, but not limited to, outcomes), and incentives for all participants. [ABSTRACT FROM AUTHOR]

Staged Diabetes Management (SDM) is a disease state management programme, that was developed by the International Diabetes Center, Minneapolis, USA. Its primary aim is to achieve near-normal to normal bloodglucose control in all patients with diabetes, using community involvement and simple, complete clinical pathways. SDM contains methods of diagnosis, an overview of therapy, practice guidelines, and specific detailed treatment protocols (decision paths) for type 1 and type 2 diabetes and gestational diabetes (GDM). Formal training in SDM was conducted for participating physicians and nurses, including an introduction to the philosophy and approach of SDM, provision of the materials and elucidation of the expected goals and results. After training and implementation, a series of trials were performed to determine the effectiveness of SDM in improving diabetes care in this region. The trial results evaluated the overall influence of SDM on such clinical parameters as HbA1c and fasting blood glucose, to assess the appropriateness of treatment modalities and timing of therapeutic choices, eg minimal delay to choice of appropriate stage. The introduction of the SDM programme led to significant reductions of HbA1c and fasting and postprandial blood sugar, without hypoglycaemia, in a representative group of people with type 1 diabetes. In patients with type 2 diabetes, significant reductions of HbA1c fasting and postprandial blood glucose without hypoglycaemia or weight-gain was achieved. To our knowledge, this is one of the first times that these goals have been achieved in people with type 1 diabetes, without hypoglycaemia, and in type 2 diabetes, without weight-gain. Using SDM we achieved 100% screening of 500 women referred for evaluation of menopausal symptoms. Approximately 5% of peri- and post-menopausal women were found to have frank diabetes (type 2) and an additional 8% had impaired glucose tolerance. Using the SDM programme, tight metabolic control in pregnant women with type 1 diabetes decreased the incidence of serious complications, eg urinary tract infections and pre-eclampsia, particularly in the critical last few weeks before delivery. We found a decrease in the incidence of serious neonatal complications in the SDM group-- lower levels of: neonatal death (none seen in the SDM group); fetal congenital malformations; hypoglycaemia and respiratory distress syndrome. With respect to GDM, screening of pregnant women and proper treatment using SDM resulted in lower pregnancy and neonatal complication rates as well as fewer Caesarean sections. The success of these early pilot studies has led to a training programme that aims to introduce SDM to up to 500 primary care providers per year throughout Poland. Once trained, a larger more definitive multi-centre study of the effects of SDM will be needed to confirm the earlier findings. [ABSTRACT FROM AUTHOR]